Page 3 of 25

PH6.1 | PH6.1 | Acid Peptic Disease Pharmacotherapy — SDL Guide — SDL Guide (Part 3)

H. pylori Eradication and Management Plans

Constructing a management plan for acid peptic disease requires integrating the pharmacological knowledge above with clinical decision-making guided by the specific condition, H. pylori status, NSAID use, and comorbidities. The single most consequential clinical decision in PUD management is whether to test for and eradicate H. pylori — this transforms a recurring, relapsing disease into one that is cured in the majority of patients with a single course of antibiotic-based therapy. Without eradication, even optimal acid suppression leaves the bacterium in place to re-inflame the mucosa, and ulcer recurrence within a year approaches 80%. A systematic approach — diagnose the condition, identify causative factors, suppress acid, eradicate the organism, remove the offending agent, and confirm cure — is the framework that separates rational pharmacotherapy from symptom chasing.

H. pylori eradication — the cornerstone of PUD management:

All patients with documented peptic ulcer disease should be tested for H. pylori (urea breath test, faecal antigen test, or rapid urease test on biopsy). If positive, eradication is mandatory. Without eradication, ulcer relapse within 1 year exceeds 80%; with successful eradication, it falls to <5%.

• First-line: Standard triple therapy — PPI (standard dose, e.g. omeprazole 20 mg) + amoxicillin 1 g + clarithromycin 500 mg, all twice daily × 14 days (14 days preferred over 7 days for higher eradication rates). Eradication rate ~80% in clarithromycin-susceptible regions.

• Second-line (clarithromycin-resistant regions, or after first-line failure): Bismuth-based quadruple therapy — PPI + bismuth subcitrate + tetracycline 500 mg + metronidazole 400 mg, all twice or thrice daily × 10–14 days. Also used as first-line in regions with >15% clarithromycin resistance (which includes parts of India).

• Alternative second-line: PPI + amoxicillin + levofloxacin (× 14 days) — used after clarithromycin failure; increasing levofloxacin resistance is a concern.

• Confirm eradication with a urea breath test or faecal antigen test ≥4 weeks after stopping antibiotics AND PPIs (PPIs suppress H. pylori density and can cause false-negative results if not stopped).

Condition-specific management plans:

Condition	First-line	Duration	Additional notes
Hp⁺ duodenal ulcer	Triple therapy (PPI + amox + clarithr)	14 days	Continue PPI 4 weeks after antibiotics for uncomplicated ulcer; 8 weeks if large ulcer
Hp⁺ gastric ulcer	Triple therapy	14 days	Continue PPI 8 weeks; repeat endoscopy to confirm healing + rule out malignancy
Hp⁻ PUD (NSAID-induced)	Stop NSAID + PPI	4–8 weeks	If NSAID cannot be stopped, use PPI co-therapy; consider COX-2 selective NSAID + PPI
Erosive GERD	PPI once daily before breakfast	4–8 weeks	Maintenance PPI if recurrence; step-down to on-demand after remission
NERD (non-erosive GERD)	PPI on-demand or H2RA	—	Step-up if insufficient
Zollinger-Ellison syndrome	PPI high dose (40–120 mg/day)	Long-term	Twice-daily PPI; titrate to gastric pH >4; investigate for MEN1
Stress ulcer (ICU)	IV famotidine or IV PPI	During critical illness	Step-down on recovery

Key drug interaction to remember: Avoid prescribing omeprazole or esomeprazole with clopidogrel — both are potent CYP2C19 inhibitors, reducing conversion of clopidogrel (prodrug) to its active thiol form, potentially compromising antiplatelet protection. Prefer pantoprazole or rabeprazole in clopidogrel-treated patients (less CYP2C19 inhibition).

H. pylori Eradication Management Flowchart

Self-Assessment — Acid Peptic Disease Pharmacotherapy

Self-assessment is not merely an examination exercise — it is the mechanism through which you consolidate pharmacological knowledge into reliable clinical judgment. The scenarios below are constructed around real prescribing decision points that a Year-2 student should be able to navigate: choosing between a PPI and an H2RA, selecting the correct H. pylori eradication regimen, identifying a drug interaction that could harm a cardiac patient, and determining the best gastroprotective strategy for a patient who cannot stop an NSAID. Work through each question by applying the taxonomy and mechanisms covered in this module, rather than guessing from drug name recognition alone. Read the explanation fully even if you answer correctly — the reasoning behind the answer is what matters for OSCE and clinical practice.

Use the micro-quiz below to test the key decision points: selection of eradication regimen, mechanism of action distinctions, drug interactions, and choosing the correct agent for the clinical context.